Results 101 to 110 of about 59,669 (311)

Test-retest variability of multifocal electroretinography in normal volunteers and short-term variability in hydroxychloroquine users

Clinical Ophthalmology, 2014
David J Browning,1 Chong Lee2 1Charlotte Eye, Ear, Nose and Throat Associates, 2University of North Carolina – Charlotte, Charlotte, NC, USA Purpose: To determine measurement variability of N1P1 amplitudes and the R1/R2 ratio in normal subjects ...
Browning DJ, Lee C
doaj  

Carbon‐ion irradiation together with autophagy inhibition and immune checkpoint inhibitors protect against pancreatic cancer development in mouse model

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
Abstract Background Pancreatic cancer remains fatal because of resistance to chemo‐, radio‐, and immunotherapies. Carbon‐ion radiotherapy (CIRT) has been beneficial for patients with pancreatic cancer. The purpose of this study was to identify the mechanism by which CIRT exerts its anticancer activity, particularly in combination with immunotherapy ...
Makoto Sudo, Yaoyao Wang, Jingren Wang, Koubun Yasuda, Keiko Mitani, Shuhei Hayashi, Masaki Ohmuraya, Hiroko Tsutsui, Jiro Fujimoto   +8 more
wiley   +1 more source

Skin Diseases in Long‐Distance Runners

JEADV Clinical Practice, EarlyView.
ABSTRACT Long‐distance running, including both road running and trail/mountain running, has significantly increased in popularity in recent years. The prolonged, repetitive physical activity combined with environmental exposures predisposes runners to a range of dermatological problems.
Henna Ahomies, Vincent Descamps, Stéphanie Leclerc‐Mercier, Nicolas Kluger   +3 more
wiley   +1 more source

Interleukin‐12/23 and Interleukin‐23 Inhibitors for the Treatment of Cutaneous Crohn's Disease: A Case Series From a Multi‐Institutional Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Cutaneous Crohn's disease (CCD) is a granulomatous condition of the skin discontiguous from the gastrointestinal tract. Cutaneous disease rarely correlates with intestinal disease and often requires separate treatment. While the use of interleukin‐12/23 (IL‐12/IL‐23) and interleukin‐23 (IL‐23) inhibitors is FDA‐approved for ...
G. E. McKay, A. Coromilas, L. Liu, K. S. Shaw, M. Murphy, N. Punyamurthy, K. M. Santiago Soltero, W. Damsky, K. A. Wanat, A. P. Charrow, M. Rosenbach, A. Caplan, C. E. LaSenna, L. Arkin, B. E. Shields   +14 more
wiley   +1 more source

Nutraceuticals and COVID‐19: A mechanistic approach toward attenuating the disease complications

Journal of Food Biochemistry, Volume 46, Issue 12, December 2022., 2022
Abstract Nutraceuticals have emerged as potential compounds to attenuate the COVID‐19 complications. Precisely, these food additives strengthen the overall COVID treatment and enhance the immunity of a person. Such compounds have been used at a large scale, in almost every household due to their better affordability and easy access.
Keshav Raj Paudel, Vyoma Patel, Sukriti Vishwas, Saurabh Gupta, Sumit Sharma, Yinghan Chan, Niraj Kumar Jha, Jesus Shrestha, Mohammad Imran, Nisha Panth, Shakti Dhar Shukla, Saurav Kumar Jha, Hari Prasad Devkota, Majid Ebrahimi Warkiani, Sachin Kumar Singh, Md Khadem Ali, Gaurav Gupta, Dinesh Kumar Chellappan, Philip M. Hansbro, Kamal Dua   +19 more
wiley   +1 more source

Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study

International Journal of Infectious Diseases, 2021
Objective: Hydroxychloroquine has been proposed as a primary prophylactic agent against coronavirus disease 2019 (COVID-19). This study aimed to investigate if patients treated with hydroxychloroquine for a non-COVID-19 indication had a lower risk of ...
Peter Kamstrup, Pradeesh Sivapalan, Josefin Eklöf, Nils Hoyer, Charlotte Suppli Ulrik, Lars Pedersen, Therese S. Lapperre, Zitta Barrella Harboe, Uffe Bodtger, Rasmus Dahlin Bojesen, Kjell E.J. Håkansson, Casper Tidemandsen, Karin Armbruster, Andrea Browatzki, Howraman Meteran, Christian Niels Meyer, Kristoffer Grundtvig Skaarup, Mats Christian Højbjerg Lassen, Jens D. Lundgren, Tor Biering-Sørensen, Jens-Ulrik Jensen   +20 more
doaj  

Systemic lupus erythematosus and cardiovascular disease

Journal of Internal Medicine, Volume 293, Issue 1, Page 48-62, January 2023., 2023
Abstract The prognosis in systemic lupus erythematosus (SLE) has improved due to better treatment and care, but cardiovascular disease (CVD) still remains an important clinical problem, since the risk of CVD in SLE is much higher than among controls.
Johan Frostegård
wiley   +1 more source

Efficacy of Calcipotriol/Betamethasone Ointment in Facial Discoid Dermatosis

JEADV Clinical Practice, EarlyView.
ABSTRACT Facial Discoid Dermatosis (FDD) is a rare chronic skin condition characterised by persistent, annular erythematous and desquamative papules on the face. Its aetiology is unclear, making differential diagnosis challenging. Key clinical features include pink‐orange, minimally scaling lesions limited to the face, sudden onset with long‐term ...
Alberto Murtas, Cristina Mugheddu, Luca Pilloni, Franco Rongioletti, Laura Atzori   +4 more
wiley   +1 more source

Diagnosis of Coxiella burnetii Prosthetic Joint Infection Using mNGS and ptNGS: A Case Report and Literature Review

Orthopaedic Surgery, Volume 15, Issue 1, Page 371-376, January 2023., 2023
Prosthetic joint infection (PJI) caused by Coxiella burnetii is rare and has atypical clinical symptoms and can cause missed diagnosis. Molecular diagnostic techniques metagenomic next‐generation sequencing (mNGS) and pathogen‐targeted next‐generation sequencing (ptNGS) are important tools for diagnosing C.
Changyu Huang, Haiqi Ding, Yiming Lin, Zeyu Zhang, Xinyu Fang, Yanshu Chen, Yang Chen, Chaofan Zhang, Wenbo Li, Wenming Zhang, Zida Huang   +10 more
wiley   +1 more source

A Case of Anti‐TNFα Therapies Induced Lupus Panniculitis Successfully Improved With a JAK Inhibitor (Baricitinib)

JEADV Clinical Practice, EarlyView.
ABSTRACT Lupus erythematosus panniculitis (LEP) is a rare variant of cutaneous lupus erythematosus (1%–3% of CLE). There are two case reports to date in the literature of LEP potentially triggered by anti‐TNF‐α therapies. Clinically, it is characterised by tender, erythematous subcutaneous indurated nodules or plaques on fatty body areas.
Cristina Grechin, Jane Doheny, Keith Pilson, Donough Howard, Muireann Roche   +4 more
wiley   +1 more source